A randomized, double-blind, placebo-controlled, multicenter, phase 2 study to evaluate the efficacy and safety of HY209 gel in patients with mild to moderate atopic Dermatitis(AD)
Ongoing
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
Phase: PHASE2 • Sponsor: Shaperon
Last updated Mar 02, 2026 15:22 UTC